Pruritus (itch sensation) is a symptom derived from many nervous system disorders that afflicts a large population of humans and is treated by a variety of pharmacological agents with variable success. Little effort has been made to develop valid animal models of itch for preclinical evaluation of potential antipruritics. Recent studies illustrate distinct species differences in the in vivo pharmacology of itch, which may contribute to different results or interpretations in itch research. Humans and monkeys have similar thresholds for detecting stimuli and the neural systems responsible for sensations in both species are fundamentally similar. Therefore, it is important to conduct studies using unanesthetized monkeys to validate animal behavioral models and to assess the effectiveness of potential antipruritics. In particular, previous studies have demonstrated that intrathecally administered morphine-induced scratching behavior in monkeys is mediated by central mu opioid receptors. Using pharmacological approaches, we intend to establish other experimental itch models using different pruritogenic agents and to determine the effectiveness of kappa opioid receptor agonists as antipruritics in a broader context in behaving monkeys. The proposed studies in this project will test the central hypothesis that activation of kappa opioid receptors attenuates itch evoked by a variety of pruritogenic agents in primates. In the proposed studies, scratching activity will be monitored by video recorders and quantified by observers blind to experimental conditions. The potential attenuation of scratching activity by rationally selected pharmacological agents will be studied in different experimental itch models. The dose- response curve, time course of each agent, and possible side effects will be thoroughly investigated. Collectively, these studies will develop valid animal models of itch, improve scientific knowledge of itch in primates, and advance the discovery of innovative therapies targeting the kappa opioid receptors for the treatment of pruritus in humans.

Public Health Relevance

Itch/Pruritus is a symptom of many clinical disorders and drug treatments that afflicts a large population of humans. However, little research has been made to improve our understanding of the receptor mechanisms of itch and potential antipruritics. The purpose of this application is to establish more experimental itch models in primates and to determine and compare the effectiveness of different drugs as potential antipruritics in a broader context. If proposed aims are achieved, it will facilitate the development of antipruritics and reduce the medical and financial burdens of itch in a global community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR059193-03
Application #
8323838
Study Section
Biobehavioral Regulation, Learning and Ethology Study Section (BRLE)
Program Officer
Tseng, Hung H
Project Start
2010-09-15
Project End
2013-04-30
Budget Start
2012-09-01
Budget End
2013-04-30
Support Year
3
Fiscal Year
2012
Total Cost
$335,880
Indirect Cost
$119,880
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schröder, W; Lambert, D G; Ko, M C et al. (2014) Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol 171:3777-800
Sukhtankar, Devki D; Lee, Heeseung; Rice, Kenner C et al. (2014) Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology (Berl) 231:1377-87
Sukhtankar, Devki D; Zaveri, Nurulain T; Husbands, Stephen M et al. (2013) Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/*-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther 346:11-22
Lin, Ann P; Ko, Mei-Chuan (2013) The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci 4:214-24
Molinari, S; Camarda, V; Rizzi, A et al. (2013) [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist. Br J Pharmacol 168:151-62
Sukhtankar, Devki D; Ko, Mei-Chuan (2013) Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One 8:e67422
Zhou, Xiaohui; Xia, Zanxian; Lan, Qin et al. (2011) BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One 6:e23629
Su, Pin-Yen; Ko, Mei-Chuan (2011) The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats. J Pharmacol Exp Ther 337:822-9